Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Highlights this week included:
Comments on USPTO humanitarian priority review voucher proposal (KEI) (Patent Docs) (PatentlyBIOtech)
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
General
Global pharmaceutical linkage regulations: A consortium framework (IP Osgoode)
Pfizer rolling out generics to grab off-patent market (GenericsWeb)
Australia: Too little too late: CSL Limited v Novo Nordisk Pharmaceuticals Pty Ltd (No 2) and the judicial discretion to amend a patent (IP Whiteboard)
Brazil: You lost your chance! Use of pipeline system (IP tango)
EU: Notes from EU Parliament meeting on innovation+access for medical technologies (KEI)
Netherlands: District Court of The Hague declares Dutch part of Bayer’s European patent covering anti-TNF alpha human monoclonal antibodies invalid (Kluwer Patent Blog)
Southeast Asia: Generic drug market picks up steam in Southeast Asia, finds Front & Sullivan (GenericsWeb)
Spain: Commercial Court No 5 of Barcelona: obtaining price for generic medicament an act of unfair competition (Kluwers Patent Blog)
US: Comments on USPTO humanitarian priority review voucher proposal (KEI) (Patent Docs) (PatentlyBIOtech)
US: Wrapping up the issues from the FDA hearings on biosimilars (Patent Docs)
US: Boston Globe Editorial acknowledges importance of gene patents, and suggests issue should be decided by Congress, not the courts (Holman’s Biotech IP Blog)
US: AntiCancer files patent infringement suit against Berthold over NightOWL image analysers (Patent Docs)
US: Regeneron sues for declaratory judgment that VEGF trap does not infringe Genentech patents (Holman’s Biotech IP Blog)
Products
Ablify (Aripiprazole) – US: Otsuka Abilify patent found valid and enforceable (Patent Docs) (GenericsWeb)
Alimta (Pemetrexed) – US: Eli Lilly’s Alimta patent found valid (Patent Docs)
Bromday (Bromfenac) – US: ISTA Pharmaceuticals granted three-year market exclusivity for Bromday (GenericsWeb)
Buspar (Buspirone), Cefzil (Cefprozil), Pravachol (Pravastatin) – US: False marking suit: Promote Innovation v Bristol-Myers Squibb Co (Patent Docs)
Cymbalta (Duloxetine) – US: Impax Laboratories receives tentative FDA approval for generic Cymbalta (SmartBrief)
Elestat (Epinastine) – US: Sandoz attempts to clear up post-Losartan ‘bottleneck’ with DJ action on disclaimed patent (FDA Law Blog)
Precedex (Dexmedetomidine) – US: Patent infringement complaint following ANDA submission: Hospira et al v Caraco Pharmaceutical (Patent Docs)
Prezista (Darunavir) – US: Tibotec and USA file separate patent infringement suits against Lupin, Mylan following Para IV certification filing (Patent Docs) (GenericsWeb)
Provigil (Modafinil) – UK: Cephalon loses UK bid to halt Mylan, Orchid generic drug sales (GenericsWeb)
Temodar (Temozolomide) – US: CAFC reverses findings of prosecution laches and inequitable conduct in Temodar case: Cancer Research Technology Ltd v Barr Laboratories, Inc. (Orange Book Blog) (Patent Docs)
Welchol (Colesevelam) – US: Impax confirms patent challenge relating to Welchol for oral suspension (SmartBrief)